<sup>18</sup>F-FDG PET/CT成像观察西妥昔单抗对结直肠癌裸鼠移植肿瘤影响的实验研究

doi:10.3877/cma.j.issn.1674-0793.2015.03.004

目的

建立结直肠癌裸鼠移植肿瘤模型,用小动物¹⁸F-FDG PET/CT技术评价西妥昔单抗对人结直肠癌移植肿瘤的影响。

方法

BALB/c裸鼠皮下分别接种人结直肠癌细胞HCT116、LIM1215,建立HCT116与LIM1215两种荷瘤裸鼠模型。将成瘤后的模型分为对照组和西妥昔单抗治疗组(n=5),并且全程观察肿瘤体积变化情况。给药1周后采用小动物¹⁸F-FDG PET/CT技术评价实体肿瘤模型,并测量各组织与器官的¹⁸F-FDG最大每克组织摄取率。

结果

小动物¹⁸F-FDG PET/CT成像显示裸鼠接种部位肿瘤内放射性摄取值增高,LIM1215与HCT116肿瘤模型的治疗组与对照组相比,肿瘤/组织或器官¹⁸F-FDG摄取比率均普遍降低,其中肿瘤/颈肌、肿瘤/心脏与肿瘤/肝脏比值差异有统计学意义(P=0.047、0.008、0.024),但两种肿瘤模型的肿瘤体积测量结果均显示,治疗组与对照组的肿瘤生长趋势差异无统计学意义。

结论

在西妥昔单抗对结直肠癌裸鼠移植肿瘤模型的治疗实验中,西妥昔单抗对肿瘤生长尚未有明显抑制作用时,小动物¹⁸F-FDG PET/CT可监测到肿瘤葡萄糖代谢的变化。

关键词: ¹⁸F-FDG, PET/CT, 西妥昔单抗, 结直肠癌, 裸鼠, 小动物

Objective

To observe the effect of cetuximab in tumor with small animal PET/CT by establishing the xenogenous implant model of colorectal cancer in nude mice.

Methods

HCT116 and LIM1215 tumor-bearing nude mouse models were developed by subcutaneous implantation of HCT116 and LIM1215 cells into BALB/c-nu mice. The tumor models were divided into the control group and cetuximab treatment group (n=5), and to observe the growth of tumor. Then the tumor models were evaluated by small animal ¹⁸F-FDG PET/CT after one week, and we measured the maximum percentage injected dose per gram from tissue and organ at the same time.

Results

The uptake of ¹⁸F-FDG in tumor tissues was significantly higher than that in normal tissues. Compared with control group, the ¹⁸F-FDG uptake rates of tumors/tissue or organ were generally lower in treatment group, which had significant difference in the ratio of tumor/neck, tumor/tumor and heart/liver (P=0.047、0.008、0.024). But the growth trends of tumor volume had no significant difference between treatment group and control group.

Conclusion

Small animal ¹⁸F-FDG PET/CT can monitor the change of glucose metabolism in tumor, while there is no obvious inhibitory effect in tumor growth with cetuximab treating xenogenous implant nude mice of colorectal cancer.

Key words: ¹⁸F-FDG, PET/CT, Cetuximab, Colorectal cancer, Nude mice, Small animal

图1 各组肿瘤模型小动物PET显像

表1 各组肿瘤模型的肿瘤/组织或器官¹⁸F-FDG摄取比率

组别	肿瘤／棕色脂肪	肿瘤／颈肌	肿瘤／心脏	肿瘤／脑	肿瘤／肾脏	肿瘤／肝脏	肿瘤／哈氏腺
A组	0.97±0.18	0.67±0.18	1.14±0.28	0.69±0.11	2.01±0.37	1.22±0.31	1.27±0.10
B组	0.42±0.25	0.41±0.07 ^a，b	0.23±0.07 ^b	0.36±0.19	1.01±0.51	1.05±0.68	0.54±0.30
C组	1.67±0.62	1.51±0.43	2.33±0.65	0.83±0.23	1.70±0.45	1.50±0.52	1.41±0.41
D组	0.75±0.35	0.86±0.35	1.31±0.58	0.75±0.20	1.49±0.40	1.34±0.32 ^c	1.03±0.42

表1 各组肿瘤模型的肿瘤/组织或器官¹⁸F-FDG摄取比率

组别	肿瘤／棕色脂肪	肿瘤／颈肌	肿瘤／心脏	肿瘤／脑	肿瘤／肾脏	肿瘤／肝脏	肿瘤／哈氏腺
A组	0.97±0.18	0.67±0.18	1.14±0.28	0.69±0.11	2.01±0.37	1.22±0.31	1.27±0.10
B组	0.42±0.25	0.41±0.07 ^a，b	0.23±0.07 ^b	0.36±0.19	1.01±0.51	1.05±0.68	0.54±0.30
C组	1.67±0.62	1.51±0.43	2.33±0.65	0.83±0.23	1.70±0.45	1.50±0.52	1.41±0.41
D组	0.75±0.35	0.86±0.35	1.31±0.58	0.75±0.20	1.49±0.40	1.34±0.32 ^c	1.03±0.42

图2 各组肿瘤/组织或器官¹⁸F-FDG摄取比率的柱状比较图

图3 各组荷瘤裸鼠肿瘤体积变化

[1]	汪建平.重视结直肠癌流行病学研究[J].中国实用外科杂志, 2013, 33(8): 622-624.
[2]	Bellomi M, Rizzo S, Travaini LL, et al. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer[J]. Radiol Med, 2007, 112(5): 681-690.
[3]	Sotelo MJ, García-Paredes B, Aguado C, et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer[J]. World J Gastroenterol, 2014, 20(15): 4208-4219.
[4]	Spindler KL, Christensen IJ, Nielsen HJ, et al. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer [J]. Tumor Biol, 2015 Jan 23. [Epub ahead of print]
[5]	Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer[J]. Drugs, 2004, 64 (1): 109-118.
[6]	VanDijk LK, Boerman OC, Franssen GM, et al. Cetuximab-F(ab′)2-SPECT and FDG-PET for prediction and response monitoring of combined modality treatment of human head and neck carcinomas in a mouse model[J]. J Nucl Med, 2014 Dec 31. [Epub ahead of print]
[7]	Aliaga A, Rousseau JA, Cadorette J, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18] fluoro-D-glucose in murine models of breast cancer[J]. Mol Imaging Biol, 2007, 9(3): 144-150.
[8]	Monazzam A, Josephsson R, Blomqvist C, et al. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer[J]. Breast Cancer Res, 2007, 9(4): 45.
[9]	Liu FY, Yen TC, Wang JY, et al. Early prediction by ¹⁸F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy[J]. Clin Nucl Med, 2015, 40(3): 200-205.
[10]	Grybauskas M, Daisne JF, Aleknavičius E, et al. Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx[J]. Medicina (Kaunas), 2014, 50(4): 245-248.
[11]	Zerizer I, Al-Nahhas A, Towey D, et al. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9): 1391-1399.
[12]	Koolen BB, Pengel KE, Wesseling J, et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1): 32-40.
[13]	Chung HW, Lee EJ, Cho YH, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma[J]. J Cancer Res Clin Oncol, 2010, 136(12): 1929-1935.
[14]	Tsuji AB, Sogawa C, Sugyo A, et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts[J]. Nucl Med Biol, 2009, 36(4): 379-388.

[1]	袁庆港, 刘理想, 张亮, 周世振, 高波, 丁超, 管文贤. 尿素-肌酐比值（UCR）可预测结直肠癌患者术后的长期预后[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 506-509.
[2]	艾贵生, 杨健, 蒋文涛. 肝移植治疗不可切除结直肠癌肝转移的研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(03): 174-180.
[3]	陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[4]	宋华传, 季鹏, 姚焕章, 王永帅, 张珅瑜, 宋瑞鹏, 王继洲. 腹腔镜肝切除术联合微波消融治疗多发性结直肠癌肝转移[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(04): 222-226.
[5]	赵泽云, 李建男, 王旻. 中性粒细胞胞外诱捕网在结直肠癌中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 524-528.
[6]	韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[7]	张金珠, 梅世文, 孙金峰, 胡刚, 邱文龙, 李国利, 汪欣, 王锡山, 汤坚强. 原发结直肠癌超系膜切除术后患者的生存危险因素分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(03): 197-204.
[8]	王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
[9]	孙晗, 于冰, 武侠, 周熙朗. 基于循环肿瘤DNA 甲基化的结直肠癌筛查预测模型的构建与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 500-506.
[10]	陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[11]	高静, 夏婷婷. 血清乳酸脱氢酶、中性粒细胞/淋巴细胞比值、血浆纤维蛋白原/前白蛋白比值对晚期结直肠癌患者姑息化疗效果与不良反应的评价[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(03): 203-207.
[12]	张朋伟, 杨朝凤, 李杨. 结直肠癌肝转移介入治疗的研究进展[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 177-182.
[13]	焦莉莉, 周芊池, 凌梦芸, 魏红玲, 徐缨. 血清SAA、CA19-9结合超声内镜对结直肠癌术前分期的诊断价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 146-150.
[14]	朱菡, 卓士超, 吴迪, 朱雅楠, 韩佳欣. 术前血浆纤维蛋白原、血脂水平及MMR表达与结直肠癌病理特点及预后的相关性[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 141-145.
[15]	王湛, 李文坤, 杨奕, 徐芳, 周敏思, 苏珈仪, 王亚丹, 吴静. 炎症指标在早发性结直肠肿瘤中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 802-810.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by ¹⁸F-FDG PET/CT

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by 18F-FDG PET/CT

Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by ¹⁸F-FDG PET/CT